Among the driver mutations in the MPNs, the mechanism by which CALR mutations activate JAK/STAT signaling is unique in that the novel C-terminus of CALR mutant proteins binds directly to MPL leading to constitutive activation [1, 2] . CALR mutants have also been shown to activate the MAPK pathway [3] . Whether CALR mutants further activate PI3K/AKT signaling is controversial, with several studies reporting a lack of (or modest) activation [2, 4] , but another demonstrating potent activation [5] . The former studies relied upon transduction of Ba/F3 TpoR cells with CALR mutant alleles whereas the latter probed the pathway in cells lines with megakaryocytic potential. Moreover, the extent to which PI3K/AKT signaling is a target in CALR mutant MPNs has been debated, with at least one study reporting that inhibitors of this pathway do not synergize with ruxolitinib [2] .
To address the discrepancy, we assayed for activation of JAK/STAT and AKT in multiple settings. First, we overexpressed the CALR type 1 (del52) and type 2 (ins5) mutants in primary murine c-kit + bone marrow progenitors and cultured the cells for 48 h. We observed enhanced activation of both STAT5 and AKT (Fig. 1a) . Next we transplanted bone marrow transduced with CALRdel52 mutant or empty vector to irradiated recipient mice and assessed AKT activation. Both intracellular flow and western blots of spleen cells revealed increase in p-AKT (Figs. 1b, c) . Finally, we assayed for total and phospho-AKT in primary CALR mutant MPN samples. We observed robust increase in AKT phosphorylation in patient derived CD34 + cells ( Fig. 1d and Supplementary Table 1 ). This was accompanied by an increase in cyclinD3 consistent with the increased proliferation of the CALR mutant cells. These cells also expressed MPL, consistent with the manner in which CALR mutants activate signaling (Fig. 1d) .
We previously reported that inhibition of AKT activity with the selective AKT inhibitor MK-2206 resulted in reduced growth of MPLW515L expressing cells both in vitro and in vivo, suggesting that this pathway is a therapeutic target in ET and PMF [6] . To determine whether CALR mutant expressing cells are similarly dependent on PI3K/AKT signaling, we treated CD34 + cells from PMF patients or healthy individuals with MK-2206. We found that CALR mutant cells were susceptible to AKT inhibition and more sensitive than healthy progenitor cells in colony assays (Figs. 1e, f). Of note, the differential effect was much more significant for megakaryocyte colonies ( Fig. 1f ) than for myeloid colonies ( Fig. 1e ), consistent with a reliance of megakaryocytes on MPL signaling. Finally, while the level of p-AKT was higher in bone marrow cells from mice transplanted with CALRdel52 expressing cells compared to those with empty vector, the degree of inhibition was similar (Fig. 1g ). MK-2206 was well tolerated in healthy C57Bl/6 mice with no evidence of myelosuppression or impaired hematopoiesis [6] . To determine the extent to which the drug suppressed thrombocytosis and megakaryopoiesis induced by mutant CALR, we transplanted CALRdel52 mutant expressing hematopoietic progenitor cells into irradiated MPN-2, and MPN-3 . The responses are significantly different as measured by 2-way ANOVA, p = 0.031 (e) and p < 0.001 (f). g Western blot and quantitation of AKT phosphorylation in bone marrow cells harvested from mice transplanted with CALRdel52 expressing cells cultured in the presence of increasing doses of MK-2206 in vitro for 24 h. Bar graphs depict mean ± SD. n = 3 biological replicates. Grb2 is included as a loading control for the western blots recipients. Recipients developed splenomegaly, hepatomegaly and thrombocytosis by 14 weeks (Fig. 2a, f) , similar to previous reports [1, 4, 7] . Treatment of mice with MK-2206 20 weeks post-transplant led to significant reductions in spleen and liver weights (Fig. 2b) , as well as the total cell count in the spleen, but not the bone marrow (Fig. 2c) . The absence of a striking bone marrow effect could be the result of a greater dependence of hematopoiesis in the spleen in this animal model. We also observed decreases in the percentages of c-kit + and CD41 + cells and the number of megakaryocytes in the spleen, but not the bone marrow ( Fig. 2d-g ). Analysis of p-AKT levels revealed decreases in both total spleen and bone marrow cells (Fig. 2h) . This inhibition of AKT signaling failed to reduce the degree of thrombocytosis (Fig. 2i) , but it did prevent a further increase in the platelet count (Fig. 2j) . MK-2206 also had no significant effect on the hematocrit or other peripheral blood parameters ( Fig. 2i and data not shown) . Given the modest effect of AKT inhibition as a single agent, we next combined MK-2206 with ruxolitinib. We observed synergy in inhibition of colony formation from murine hematopoietic progenitor cells expressing CALRdel52 (Supplementary  Table 2 ). Of note, CFU-Mk assays revealed a much stronger synergy of MK-2206 with ruxolitinib than myeloid colonies. These results suggest that although MK-2206 showed modest activity as a single agent, combining it with ruxolitinib may enhance the anti-tumor effect of both drugs, especially against cells that are dependent upon MPL. Although ruxolitinib shows similar efficacy patients with any of the three driver mutations [8] , it has limited use in that most patients progress or become intolerant within 2-3 years [9] . Therefore, novel agents to enhance or follow ruxolitinib are needed. Here we demonstrate that AKT signaling is indeed increased in CALR mutant MPN patients and further reveal that AKT is a therapeutic target in this group of patients. With development of new PI3K/AKT inhibitors, inhibition of this pathway should be pursued in combination with ruxolitinib for the group of patients with CALR mutations. 
